Latest Deals
Credit:
Danaher agrees to acquire UK’s Abcam for $5.7bn
Global science and technology provider Danaher has signed a definitive agreement for the acquisition of all outstanding stakes in UK-based protein consumables supplier Abcam in a deal valued at $5.7bn. Danaher will finance the transaction by leveraging cash in hand, along with proceeds from the issuing commercial paper.
Abcam was established in 1998 and focuses on delivering antibodies and re-agents to address targets in biological pathways vital for progressing drug development and research in the life sciences sector.
Ibex lands $55m in Series C funding
Israel-based cancer diagnostics firm Ibex Medical Analytics has announced the close of a Series C financing round, accumulating a total of $55 million in funds and bringing its total funding pot to over $100 million. The Series C funding was led by 83North, who were joined by Sienna Venture Capital, Octopus Ventures, aMoon, Planven Entrepreneur Ventures and Dell Technologies Capital.
Abbott signs definitive agreement to acquire Bigfoot Biomedical
Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Financial terms of the deal were not disclosed. The transaction is anticipated to close in the third quarter of this year.
AI drug discovery company Genesis Therapeutics wins $200m in Series B round
Artificial intelligence (AI)-led drug development company Genesis Therapeutics has raised $200m in Series B financing. Returning investor a16z Bio + Health and an unnamed US-based life sciences investor co-led the round with participation from new investors, including the venture capital arm of NVIDIA – a company considered a global leader in AI technology.
